CA3123869A1 - Compounds that participate in cooperative binding and uses thereof - Google Patents
Compounds that participate in cooperative binding and uses thereof Download PDFInfo
- Publication number
- CA3123869A1 CA3123869A1 CA3123869A CA3123869A CA3123869A1 CA 3123869 A1 CA3123869 A1 CA 3123869A1 CA 3123869 A CA3123869 A CA 3123869A CA 3123869 A CA3123869 A CA 3123869A CA 3123869 A1 CA3123869 A1 CA 3123869A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- optionally substituted
- compound
- alkylene
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783816P | 2018-12-21 | 2018-12-21 | |
| US62/783,816 | 2018-12-21 | ||
| US201962894493P | 2019-08-30 | 2019-08-30 | |
| US62/894,493 | 2019-08-30 | ||
| US201962930489P | 2019-11-04 | 2019-11-04 | |
| US62/930,489 | 2019-11-04 | ||
| PCT/US2019/068100 WO2020132597A1 (en) | 2018-12-21 | 2019-12-20 | Compounds that participate in cooperative binding and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3123869A1 true CA3123869A1 (en) | 2020-06-25 |
Family
ID=71099011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3123869A Pending CA3123869A1 (en) | 2018-12-21 | 2019-12-20 | Compounds that participate in cooperative binding and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20200197391A1 (https=) |
| EP (1) | EP3897644A4 (https=) |
| JP (2) | JP7721052B2 (https=) |
| KR (1) | KR20210116479A (https=) |
| CN (1) | CN113498342A (https=) |
| AU (2) | AU2019401466B2 (https=) |
| BR (1) | BR112021012057A2 (https=) |
| CA (1) | CA3123869A1 (https=) |
| IL (2) | IL317393A (https=) |
| MX (2) | MX2021007468A (https=) |
| SA (1) | SA521422304B1 (https=) |
| SG (1) | SG11202106605VA (https=) |
| TW (1) | TW202600561A (https=) |
| WO (1) | WO2020132597A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116284045A (zh) * | 2023-05-18 | 2023-06-23 | 西南交通大学 | 一种手性吲哚单元取代的四氢异喹啉化合物及其合成方法 |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201629069A (zh) * | 2015-01-09 | 2016-08-16 | 霍普驅動生物科技股份有限公司 | 參與協同結合之化合物及其用途 |
| KR102598895B1 (ko) | 2016-07-12 | 2023-11-07 | 레볼루션 메디슨즈, 인크. | 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진 |
| MX2019008695A (es) | 2017-01-23 | 2019-09-11 | Revolution Medicines Inc | Compuestos biciclicos como inhibidores alostericos de shp2. |
| MX2019008696A (es) | 2017-01-23 | 2019-09-13 | Revolution Medicines Inc | Compuestos de piridina como inhibidores de shp2 alostericos. |
| MX2020003579A (es) | 2017-10-12 | 2020-07-22 | Revolution Medicines Inc | Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos. |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| KR20210116479A (ko) * | 2018-12-21 | 2021-09-27 | 레볼루션 메디슨즈, 인크. | 공동 결합에 참여하는 화합물 및 그의 용도 |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN120699039A (zh) * | 2019-11-04 | 2025-09-26 | 锐新医药公司 | Ras抑制剂 |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| US20210322405A1 (en) * | 2020-04-15 | 2021-10-21 | Washington University | Compositions and methods for treating cancer |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| AU2021401741A1 (en) * | 2020-12-17 | 2023-06-29 | Blossomhill Therapeutics, Inc. | Macrocycles and their use |
| CN116635076A (zh) * | 2020-12-17 | 2023-08-22 | 荣山医药股份有限公司 | 大环化合物及其用途 |
| IL307396A (en) * | 2021-04-02 | 2023-12-01 | Massachusetts Gen Hospital | Methods for inhibiting RAS |
| US20240217960A1 (en) * | 2021-04-09 | 2024-07-04 | Universität Basel | Triazine derivative as covalent inhibitors of pi3k |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| CA3217393A1 (en) | 2021-05-05 | 2022-11-10 | Elena S. Koltun | Ras inhibitors |
| AU2022268962A1 (en) * | 2021-05-05 | 2023-12-14 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| MX2023013912A (es) | 2021-05-25 | 2024-02-12 | Revolution Medicines Inc | Metodos para inhibir ras. |
| EP4346826A4 (en) * | 2021-05-27 | 2025-04-30 | Mirati Therapeutics, Inc. | COMBINATION THERAPIES |
| WO2023015559A1 (en) * | 2021-08-13 | 2023-02-16 | Nutshell Biotech (Shanghai) Co., Ltd. | Macrocycle compounds as inhibitors of ras |
| AR126854A1 (es) | 2021-08-27 | 2023-11-22 | Hoffmann La Roche | Compuestos macrocíclicos para el tratamiento de cáncer |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| TW202400607A (zh) * | 2022-04-25 | 2024-01-01 | 美商翰森生物有限責任公司 | 環狀化合物、製備方法及其醫藥用途 |
| CN119301132A (zh) | 2022-06-01 | 2025-01-10 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的卤代吲哚大环化合物 |
| WO2023240263A1 (en) * | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| EP4582426A4 (en) * | 2022-09-19 | 2025-12-24 | Adlai Nortye Biopharma Co Ltd | PAN-KRAS INHIBITOR COMPOUND |
| CN117720556A (zh) * | 2022-09-19 | 2024-03-19 | 杭州阿诺生物医药科技有限公司 | 一种pan-KRAS抑制剂化合物及其制备方法和用途 |
| CN119522225A (zh) | 2022-09-29 | 2025-02-25 | 广州嘉越医药科技有限公司 | 大环衍生物及其应用 |
| CN118373832B (zh) * | 2023-01-20 | 2025-01-28 | 深圳晶蛋生物医药科技有限公司 | 大环类化合物、其药物组合物及其应用 |
| CR20250329A (es) | 2023-02-14 | 2025-09-12 | Hoffmann La Roche | Compuestos tricíclicos para el tratamiento del cáncer |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CN121263418A (zh) | 2023-04-07 | 2026-01-02 | 锐新医药公司 | 大环ras抑制剂 |
| KR20260005904A (ko) | 2023-04-07 | 2026-01-12 | 레볼루션 메디슨즈, 인크. | 매크로사이클릭 ras 억제제 |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
| EP4720072A2 (en) * | 2023-05-26 | 2026-04-08 | Revolution Medicines, Inc. | Ras inhibitors |
| CN116570599B (zh) * | 2023-07-04 | 2023-10-20 | 四川大学华西医院 | Vs6766联合ly3009120的应用及药物组合物 |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025090809A1 (en) * | 2023-10-25 | 2025-05-01 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| CN117567483B (zh) * | 2023-11-23 | 2025-10-21 | 济南市中心医院 | 一种通过金催化的不对称环加成反应及动力学拆分合成手性氮杂八元环类化合物的方法 |
| WO2025162395A1 (zh) * | 2024-02-01 | 2025-08-07 | 山东先声生物制药有限公司 | 吲哚衍生物作为ras抑制剂及其应用 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025214350A1 (en) * | 2024-04-08 | 2025-10-16 | Sunrise Oncology (Hong Kong) Limited | Macrocyclic compounds as ras inhibitors for the treatment of cancer |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026046393A1 (zh) * | 2024-09-02 | 2026-03-05 | 山东先声再明生物制药有限公司 | 吲哚类衍生物的制备及其应用 |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601852B2 (en) * | 2006-05-11 | 2009-10-13 | Kosan Biosciences Incorporated | Macrocyclic kinase inhibitors |
| AU2011214135B2 (en) * | 2010-02-09 | 2014-07-31 | Neurovive Pharmaceutical Ab | Sanglifehrin based compounds |
| AU2012257513B2 (en) * | 2011-05-19 | 2017-05-11 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Macrocyclic compounds as protein kinase inhibitors |
| AR091279A1 (es) * | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| KR20240093922A (ko) * | 2017-04-05 | 2024-06-24 | 레볼루션 메디슨즈, 인크. | 단백질-단백질 계면을 분석하기 위한 방법 및 시약 |
| KR20210116479A (ko) * | 2018-12-21 | 2021-09-27 | 레볼루션 메디슨즈, 인크. | 공동 결합에 참여하는 화합물 및 그의 용도 |
-
2019
- 2019-12-20 KR KR1020217022312A patent/KR20210116479A/ko active Pending
- 2019-12-20 JP JP2021535755A patent/JP7721052B2/ja active Active
- 2019-12-20 IL IL317393A patent/IL317393A/en unknown
- 2019-12-20 TW TW114110001A patent/TW202600561A/zh unknown
- 2019-12-20 CA CA3123869A patent/CA3123869A1/en active Pending
- 2019-12-20 AU AU2019401466A patent/AU2019401466B2/en active Active
- 2019-12-20 BR BR112021012057-2A patent/BR112021012057A2/pt unknown
- 2019-12-20 IL IL284210A patent/IL284210B2/en unknown
- 2019-12-20 CN CN201980092760.0A patent/CN113498342A/zh active Pending
- 2019-12-20 EP EP19901393.9A patent/EP3897644A4/en active Pending
- 2019-12-20 MX MX2021007468A patent/MX2021007468A/es unknown
- 2019-12-20 WO PCT/US2019/068100 patent/WO2020132597A1/en not_active Ceased
- 2019-12-20 US US16/723,438 patent/US20200197391A1/en not_active Abandoned
- 2019-12-20 SG SG11202106605VA patent/SG11202106605VA/en unknown
-
2021
- 2021-06-17 SA SA521422304A patent/SA521422304B1/ar unknown
- 2021-06-18 MX MX2025001810A patent/MX2025001810A/es unknown
-
2023
- 2023-03-16 US US18/184,766 patent/US20240139185A1/en not_active Abandoned
-
2024
- 2024-11-22 JP JP2024203859A patent/JP2025037925A/ja active Pending
-
2025
- 2025-07-16 AU AU2025205500A patent/AU2025205500A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116284045A (zh) * | 2023-05-18 | 2023-06-23 | 西南交通大学 | 一种手性吲哚单元取代的四氢异喹啉化合物及其合成方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019401466A1 (en) | 2021-07-01 |
| SA521422304B1 (ar) | 2023-12-21 |
| TW202600561A (zh) | 2026-01-01 |
| JP2025037925A (ja) | 2025-03-18 |
| MX2021007468A (es) | 2021-08-05 |
| AU2019401466B2 (en) | 2025-04-24 |
| US20200197391A1 (en) | 2020-06-25 |
| US20240139185A1 (en) | 2024-05-02 |
| KR20210116479A (ko) | 2021-09-27 |
| IL284210B2 (en) | 2025-05-01 |
| WO2020132597A1 (en) | 2020-06-25 |
| AU2025205500A1 (en) | 2025-07-31 |
| IL284210A (en) | 2021-08-31 |
| EP3897644A4 (en) | 2022-09-07 |
| BR112021012057A2 (pt) | 2021-10-19 |
| JP2022520154A (ja) | 2022-03-29 |
| SG11202106605VA (en) | 2021-07-29 |
| TW202039509A (zh) | 2020-11-01 |
| CN113498342A (zh) | 2021-10-12 |
| IL317393A (en) | 2025-02-01 |
| JP7721052B2 (ja) | 2025-08-12 |
| MX2025001810A (es) | 2025-03-07 |
| WO2020132597A8 (en) | 2020-07-16 |
| IL284210B1 (en) | 2025-01-01 |
| EP3897644A1 (en) | 2021-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240139185A1 (en) | Compounds that participate in cooperative binding and uses thereof | |
| JP7823816B2 (ja) | Ｒａｓ阻害剤 | |
| AU2022270116A1 (en) | Ras inhibitors | |
| AU2023204824A1 (en) | Ras inhibitors | |
| CA3234100A1 (en) | Ras inhibitors | |
| AU2022268962A1 (en) | Ras inhibitors for the treatment of cancer | |
| US20230100838A1 (en) | Covalent ras inhibitors and uses thereof | |
| WO2024211712A1 (en) | Condensed macrocyclic compounds as ras inhibitors | |
| AU2024281092A1 (en) | Ras inhibitors | |
| US20240262847A1 (en) | Covalent ras inhibitors and uses thereof | |
| RU2858913C2 (ru) | Соединения, которые участвуют в кооперативном связывании, и их применение | |
| TWI917313B (zh) | 參與協同結合之化合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220816 |
|
| C11 | Application revival requested |
Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED Effective date: 20250204 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250204 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250221 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250312 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250312 |